 Connection
Ann Thor to Neoplasm Proteins
This is a "connection" page, showing publications Ann Thor has written about Neoplasm Proteins.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.324 |
|
|
|
-
Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Torkko KC, Edgerton SM, Lucia MS, Ray R, Thor AD, Porter CC, Lambert JR. Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. Oncotarget. 2016 Mar 29; 7(13):15757-71.
Score: 0.106
-
Thor AD, Koerner FC, Edgerton SM, Wood WC, Stracher MA, Schwartz LH. pS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival. Breast Cancer Res Treat. 1992; 21(2):111-9.
Score: 0.079
-
Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP, Chambon P, Thor AD. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res. 1991 Jan 15; 51(2):624-8.
Score: 0.074
-
Scott GK, Chang CH, Erny KM, Xu F, Fredericks WJ, Rauscher FJ, Thor AD, Benz CC. Ets regulation of the erbB2 promoter. Oncogene. 2000 Dec 18; 19(55):6490-502.
Score: 0.037
-
Krajewski S, Thor AD, Edgerton SM, Moore DH, Krajewska M, Reed JC. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res. 1997 Feb; 3(2):199-208.
Score: 0.028
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|